Product line withdrawal: status management and the cost implications of the no-longer-placed flag

This article is the 45th instalment of Volume 5, Post-market Compliance and Regulatory Developments, of the 50-part series on medical device registration in Switzerland. Together with the remaining nine articles of this volume it forms the complete deliverable on this topic. The publication timestamp, article number, title and unique URL are set out in the table below.

1. Key takeaways

Flagging a device as No longer placed on the market in swissdamed has one direct consequence: the device stops counting towards the annual registration fee. But the same device, once invalidated, must be registered again and charged again if it returns. Product line withdrawal is therefore not a purely technical action in the registration database; it is a financial decision. Withdraw too fast and you cut the channel for subsequent sales, because restoring a status costs money rather than nothing. Withdraw too slow and every device kept in the wrong status keeps generating CHF 20 per year. The cost structure of swissdamed thus turns a status field into a budgeting variable, and the companies that manage it deliberately, with quarterly reconciliation between the sales ledger and the registration database, spend measurably less than the companies that treat the database as a formality.

2. Legal basis

3. Expert insights

1. The billing anchor is the status on a single day, not whether the device sold during the year. The first billing time point is 31 December 2026, and it covers all UDI-DI whose status on that day is On the market; UDI-DI with the status No longer placed on the market on that day are not billed. From 1 January 2027, regular billing applies to registrations newly added during the year. The judgement behind this design is administrative economy: a single snapshot day replaces a full year of accumulated tracking, which keeps the fee system cheap to operate. The counterpoint is that it compresses the withdrawal action into a single deadline. Companies must run a full status reconciliation before the fourth quarter ends, or they will pay for product items that have already stopped selling.

2. The cap makes economies of scale flatten out at 491 devices. The rate is CHF 200 for the first UDI-DI, CHF 20 for each additional UDI-DI within the same calendar year, and a cap of CHF 10,000 per manufacturer or SPPP per year. On these figures the cap is reached at 491 devices, and no further devices are billed from the 492nd onwards. The trade-off favours large catalogues, but with an important structural catch: the fees accumulate at the level of the manufacturer or SPPP, not at the level of the CH-REP. A group with multiple brands or multiple legal entities cannot pool its devices to share one cap, so the legal-entity architecture directly determines the cost. Consolidation decisions made for commercial reasons will show up in the fee calculation.

3. The line between free and not free must be drawn precisely. Data updates are free of charge; re-registration after invalidation is charged again. Taken together, these two rules form a hard constraint on withdrawal decisions. A single mis-flagging, or a single invalidation made to save CHF 20, can become expensive if the product later needs to be restored, because the restoration is billed again as a first or additional UDI-DI. As a practical estimate, for items that are only suspended from sale with a realistic prospect of resumption, remaining on the register is usually more economical than invalidation. Note also that for foreign entities the bill is sent to their CH-REP, which should be built into the internal reconciliation process so invoices do not sit unnoticed at the representative’s office.

4. Practical recommendations

1. Establish a quarterly reconciliation mechanism for the UDI-DI ledger, focusing on items that have stopped selling but are still flagged as On the market.
2. Complete one full status confirmation before the first billing snapshot on 31 December 2026, and retain the reconciliation records.
3. Separate the two operation types, data updates and re-registration after invalidation: the former is free, the latter is charged again, and their approval paths should be separate.
4. Calculate the annual fee at the manufacturer or SPPP level, check the distance to the CHF 10,000 cap, and optimise the legal-entity and brand allocation accordingly.
5. Agree an invoice-forwarding and reconciliation process with the CH-REP for foreign entities, so no bill lingers at the representative and late-payment risk is avoided.

5. Verification checklist

• □ The UDI-DI ledger and the statuses in swissdamed match line by line.
• □ All status updates before the snapshot day of 31 December 2026 are confirmed as effective.
• □ The annual fee has been calculated at the manufacturer or SPPP level, checked against the 491-device and CHF 10,000 cap points.
• □ The rule that data updates are free while re-registration after invalidation is charged again is recorded in the internal finance SOP.
• □ An invoice-forwarding and reconciliation process with the CH-REP is in place for foreign entities.
• □ Devices subject to serious incident, FSCA or trend reporting are confirmed registered without transition from 1 July 2026.

Legal information verified as of 29 October 2026.

GRZAN supports manufacturers entering or operating in the Swiss market with post-market compliance services, covering vigilance reporting, field safety corrective actions and Swissmedic inspection readiness. Our team manages swissdamed status reconciliation against the FeeO-Swissmedic billing rules, tracks the snapshot-day deadline and aligns fee allocation with your legal-entity structure. For support with your Swiss post-market obligations, contact info@grzanglobal.com.